Adobe Flash Player is required to view this content.

Welcome to HemaCare Corporation – a leading global provider of biological blood products and services since 1978.

HemaCare Corporation is a blood services company serving healthcare providers and the scientific community for over 30 years. HemaCare and its subsidiary, Coral Blood Services, perform therapeutic apheresis services, provide human-derived biological products, and support the implementation of cellular therapy based trials with apheresis collections. Learn more

RESEARCH PRODUCTS

HemaCare provides a variety of human primary blood cells such as lymphocytes, monocytes, neutrophils, CD34+ and CD133+ stem cells, serum and much more!

  • Normal donor subjects and patients
  • Normal and mobilized peripheral blood
  • Apheresis and whole blood derived

Human Peripheral Blood

Human Peripheral Blood

 

 

CELLULAR THERAPY

Quality of living cellular raw material is a major determinant of final product characteristics. Controlling and qualifying the cell collection step is essential to minimizing operational sources of variability, and greatly increases the likelihood of success in manufacturing. HemaCare’s specialty is apheresis collection, and, building on over 30 years of experience, has addressed this need for optimized cell collection with a program for controlling and qualifying its apheresis procedures and collection sites, bringing a higher degree of reproducibility to research projects or manufacturing efforts based on cGMP and cGTP principles.

Sourcing Human Blood-Derived Raw Material: Optimization, Qualification and Control
Click here to view the presentation

THERAPEUTIC APHERESIS SAMPLE ORDER FORMS

ANNOUNCEMENTS

News

Tue, 07 Feb 2012 08:09:37 GMT

Researchers at Keck discover new stem cell

Sun, 05 Feb 2012 16:55:30 GMT

New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of Arcelis Immunotherapy AGS-003

Wed, 01 Feb 2012 15:11:19 GMT

Stem Cell Therapy Shows Promise for Stroke, Studies Say

Wed, 01 Feb 2012 13:09:24 GMT

Dendreon Announces CEO and Chairman Succession Plan

Tue, 31 Jan 2012 16:10:13 GMT

Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)

Thu, 26 Jan 2012 16:01:20 GMT

Amgen to Acquire Micromet

Tue, 24 Jan 2012 19:42:10 GMT

Roswell Park trial seeks to fight, prevent cancer

Mon, 23 Jan 2012 20:14:12 GMT

Small Stem Cell Study Claims Early Success in Treating Eye Disease

Mon, 23 Jan 2012 14:10:11 GMT

ImmunoCellular Therapeutics Ltd : ImmunoCellular Therapeutics Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma

Wed, 18 Jan 2012 23:17:25 GMT

Genzyme revives Fabrazyme with EMA plant OK

Mon, 16 Jan 2012 16:47:28 GMT

Man’s Life Saved With Artificial Trachea Using Stem Cells

Fri, 13 Jan 2012 16:44:33 GMT

University of Kentucky offers stroke stem cell trial

Wed, 11 Jan 2012 14:20:43 GMT

Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012

Tue, 10 Jan 2012 08:11:45 GMT

ASCO's Annual Progress Report Cites Significant Advances for 2011

Mon, 09 Jan 2012 14:40:15 GMT

NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011

 

Events

11.23.2011 HemaCare will be presenting and exhibiting at Biopharmaceutical Development and Production Week: Biopharmaceutical Raw Materials throughout the Product Lifecycle Conference taking place from February 27 - 28, 2012 in San Diego, CA. Stop by booth #205 and say hello and learn more about our products and services. For more information on the meeting, please visit www.ibclifesciences.com

 

More News & Events

 

E-NEWSLETTER SIGN UP